Boehringer in research collaboration with Domain Therapeutics
04-12-2018
filograph / iStockphoto.com
Boehringer Ingelheim has teamed up with academic institutions and research companies in the UK to develop a long-term gene therapy for cystic fibrosis, according to a statement released on Monday, August 6.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Boehringer, Imperial Innovations, Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, gene therapy, research and development, commercialisation
